Summary
enGene Therapeutics reported updated interim data from its pivotal LEGEND study that showed a decline in measured efficacy, prompting downgrades from five Wall Street firms. The company's anytime complete response (CR) rate fell to 54% from a previously reported 63%, a change analysts say was concentrated among patients enrolled after October 2025 - a period that followed protocol amendments. The shift has raised questions about the drug's commercial viability in a competitive treatment environment.
Trial data and timing
The updated figures show the anytime CR rate decreased to 54% from 63%. Analysts point to a particular deterioration among patients enrolled after October 2025. That later-enrolled cohort followed what market participants had viewed as constructive changes to the trial protocol, but company management has not provided an explanation for the efficacy decline.
Analyst reactions
Several sell- and neutral-side analysts adjusted their recommendations and valuation assumptions after the data update. Raymond James analyst Sean McCutcheon cut his rating to Outperform from Strong Buy and reduced his price target to $4 from $27, citing that the CR rate for post-protocol patients fell from 63% to 39% and noting that management was unable to explain the dramatic drop-off in efficacy.
Guggenheim analyst Michael Schmidt moved to Neutral and wrote that enGene now clearly falls short of contemporary therapies, adding that physician feedback indicates a roughly 40% 12-month CR as a minimum threshold to support meaningful commercial use. Oppenheimer analyst Leland Gershell downgraded the stock to Perform and described the company as a "show-me" story that will face constrained investor enthusiasm in the near term.
Piper Sandler analyst Allison Bratzel lowered ENGN to Neutral with a $4 price target, pointing to uncertainty in the data and leadership concerns tied to an updated employment agreement that creates an exit path for the chief medical officer after June 1.
Market valuation and cash position
Citizens analyst Silvan Turkcan noted that enGene's shares trade at a 63% discount to the company's stated $313 million in cash reserves, characterizing the stock as "fairly valued amongst biotech peers with similar development program uncertainties." The shares were trading near $1.63, down roughly $0.09 or 5.23% intraday according to available market ticks.
Implications for commercialization
Analysts said the updated efficacy profile complicates enGene's commercial case. With physician feedback pointing to a minimum bar of about a 40% 12-month CR for meaningful uptake, the deterioration in response rates for later-enrolled patients is a central concern for future adoption and competitive positioning.
Conclusion
The combination of weaker-than-expected interim efficacy, downward analyst revisions and questions around leadership and clarity from management has shifted investor sentiment. For now, the story centers on reconciling the post-October 2025 performance difference and determining whether further data or explanation can restore confidence in the program.